Q1 EPS Forecast for Bolt Biotherapeutics Boosted by Analyst

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Research analysts at Leerink Partnrs boosted their Q1 2025 EPS estimates for Bolt Biotherapeutics in a report released on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn ($0.34) per share for the quarter, up from their prior forecast of ($0.41). The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.23) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%.

Other equities analysts also recently issued reports about the stock. HC Wainwright reiterated a “neutral” rating on shares of Bolt Biotherapeutics in a report on Tuesday. Stifel Nicolaus cut their target price on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research note on Tuesday. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $1.13.

Bolt Biotherapeutics Trading Down 0.1 %

BOLT stock opened at $0.44 on Friday. Bolt Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.56. The stock has a market capitalization of $16.82 million, a price-to-earnings ratio of -0.26 and a beta of 0.94. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21. The firm’s fifty day simple moving average is $0.47 and its two-hundred day simple moving average is $0.55.

Institutional Investors Weigh In On Bolt Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. FMR LLC increased its stake in shares of Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares during the period. Millennium Management LLC bought a new position in Bolt Biotherapeutics during the 4th quarter worth about $25,000. Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics during the 4th quarter valued at about $42,000. Squarepoint Ops LLC bought a new stake in shares of Bolt Biotherapeutics in the 4th quarter valued at about $26,000. Finally, Velan Capital Investment Management LP purchased a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth approximately $27,000. 86.70% of the stock is owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.